Tolvaptan maintains diuretic action in hemodialysis patients


Tolvaptan is an oral aquaretic agent which selectively antagonizes arginine vasopressin V2 receptors and increases free water excretion. A total of 124 hemodialyzed patients with preserved diuresis were recruited in a randomized, double-blind, placebo-controlled, Phase 2 trial to assess tolvaptan efficacy and safety. They were randomized to receive oral tolvaptan 15 mg/day or 30 mg/day, or placebo for 24 weeks. Tolvaptan treatment sustained diuretic action, but did not significantly reduce total fluid removal by hemodialysis or interdialytic weight gain. The drug was safe and well-tolerated during the study period.

Read the full article here: